Centessa Pharmaceuticals (CNTA) Receivables Refunds: 2022-2025
Historic Receivables Refunds for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $49.1 million.
- Centessa Pharmaceuticals' Receivables Refunds rose 44.35% to $49.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.1 million, marking a year-over-year increase of 44.35%. This contributed to the annual value of $43.8 million for FY2024, which is 15.73% up from last year.
- Latest data reveals that Centessa Pharmaceuticals reported Receivables Refunds of $49.1 million as of Q3 2025, which was up 20.68% from $40.7 million recorded in Q2 2025.
- Centessa Pharmaceuticals' Receivables Refunds' 5-year high stood at $49.6 million during Q1 2025, with a 5-year trough of $18.9 million in Q2 2022.
- For the 3-year period, Centessa Pharmaceuticals' Receivables Refunds averaged around $37.2 million, with its median value being $37.8 million (2023).
- Per our database at Business Quant, Centessa Pharmaceuticals' Receivables Refunds soared by 78.53% in 2024 and then dropped by 2.87% in 2025.
- Quarterly analysis of 4 years shows Centessa Pharmaceuticals' Receivables Refunds stood at $24.2 million in 2022, then skyrocketed by 56.49% to $37.8 million in 2023, then grew by 15.73% to $43.8 million in 2024, then surged by 44.35% to $49.1 million in 2025.
- Its Receivables Refunds stands at $49.1 million for Q3 2025, versus $40.7 million for Q2 2025 and $49.6 million for Q1 2025.